Flashcards in RESIDENCY Deck (38):
1
When to do ABG after hooking to mech vent
Within an hour
2
Mech vent: How to set TV
6-8cc/kg
3
Mech vent: How to set FiO2
Begin wih 100, wean as tolerated
4
Mech vent: How to set PEEP
Begin with 5
5
ABG parameter to measure oxygenation
PO2
6
ABG parameter to measure ventilation
PCO2
7
Parameters to manipulate to alter oxygenation (PO2)
1) FiO2
2) PEEP
3) I-time
8
Parameters to manipulate to alter ventilation (PCO2)
1) RR
2) TV
3) Shorten I-time to lengthen E-time
9
Proper ET size
(Age/4) + 4 OR
10
ET length
Size x 3 OR
Wt. + 6 OR
(Age/2) + 12
11
Mech vent: How to set rate
Infant: 25-30/min
Child: 15-20/min
Teen: 10-14/min
12
Incidence of hemophilia A
1/10,000 male births
13
Incidence of hemophilia B
1/30,000 male births
14
Symptomatic female carriers of hemophilia A
30%
15
Factors that increase risk of inhibitor development
Surgery
Infection
Most important: Genetics (gene mutation)
16
% factor activity goal in hemophilia in Phils in factor transfusion
60-80%
(100% in developed countries)
17
% factor activity for adequate hemostasis (hemophilia)
30%
18
How to screen for inhibitors in patients with hemophilia
Mixing studies (px plasma + normal plasma --> aPtt: 60% increase from baseline = no inhibitor)
19
Indications for admission of hemophiliac patients
1) Life-threatening bleed (excluding hemarthroses)
2) Non-life-threatening bleed IF known to have inhibitor
20
Phenobarbital, side effect (WOF when loading)
Respiratory depression
21
Incidence of hemophilia A
1/10,000 male birthd
22
Incidence of hemophilia B
1/30,000 male births
23
Symptomatic female carriers of hemophilia A
30%
24
Factors that increase risk of inhibitor development
Surgery
Infection
Most important: Genetics (gene mutation)
25
% factor activity goal in hemophilia in Phils in factor transfusion
60-80%
(100% in developed countries)
26
% factor activity for adequate hemostasis (hemophilia)
30%
27
How to screen for inhibitors in patients with hemophilia
Mixing studies (px plasma + normal plasma --> aPtt: 60% increase from baseline = no inhibitor)
28
Indications for admission of hemophiliac patients
1) Life-threatening bleed (excluding hemarthroses)
2) Non-life-threatening bleed IF known to have inhibitor
29
Phenobarbital, side effect (WOF when loading)
Respiratory depression
30
Incidence of hemophilia A
1/10,000 male birthd
31
Incidence of hemophilia B
1/30,000 male births
32
Symptomatic female carriers of hemophilia A
30%
33
Factors that increase risk of inhibitor development
Surgery
Infection
Most important: Genetics (gene mutation)
34
% factor activity goal in hemophilia in Phils in factor transfusion
60-80%
(100% in developed countries)
35
% factor activity for adequate hemostasis (hemophilia)
30%
36
How to screen for inhibitors in patients with hemophilia
Mixing studies (px plasma + normal plasma --> aPtt: 60% increase from baseline = no inhibitor)
37
Indications for admission of hemophiliac patients
1) Life-threatening bleed (excluding hemarthroses)
2) Non-life-threatening bleed IF known to have inhibitor
38